GeneDx Holdings (WGS) Total Liabilities (2020 - 2026)

GeneDx Holdings (WGS) has reported Total Liabilities for 7 consecutive years, with $237.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Liabilities rose 27.06% year-over-year to $237.3 million in Q2 2026; TTM through Jun 2026 was $237.3 million, a 27.06% increase from a year earlier, with the FY2025 full-year figure at $215.5 million, up 23.77% from the prior year.
• Total Liabilities was $237.3 million for Q2 2026 at GeneDx Holdings, down from $252.2 million in the prior quarter.
• Over five years, Total Liabilities peaked at $296.0 million in Q2 2022 and troughed at $163.0 million in Q3 2023.
• A 5-year average of $210.2 million and a median of $198.4 million in 2024 frame the typical range for Total Liabilities.
• The widest YoY moves for Total Liabilities: up 42.92% in 2022, down 53.72% in 2022.
• Over 5 years, Total Liabilities stood at $237.2 million in 2022, then slipped by 19.6% to $190.7 million in 2023, then dropped by 8.71% to $174.1 million in 2024, then increased by 23.77% to $215.5 million in 2025, then advanced by 10.09% to $237.3 million in 2026.
• The last three Total Liabilities figures came in at $237.3 million (Q2 2026), $252.2 million (Q1 2026), and $215.5 million (Q4 2025), per Business Quant data.